$BIIB

AI Analysis

Generated on May 11, 2026

AI Score
58/ 100
Hold$BIIB

Biogen Inc.

$BIIBNASDAQHealthcareLarge-Cap

Biogen develops and commercializes therapies for neurological diseases including multiple sclerosis and Alzheimer's.

Market Cap
$25.0B
Revenue (TTM)
$9.5B
-3.0%
Net Income (TTM)
$1.8B
-10.0%
EPS (TTM)
$12.50
P/E Ratio
14.0
Dividend Yield
0.0%
52-Week Range
$150-$280
Beta
0.42
Dimension Scores
Fundamental
56
Technical
54
Sentiment
58
Risk / Reward
62
Momentum
52
FundTechSentRiskMome
Financial Health
Profitability
61moderate
Growth
55moderate
Liquidity
70strong
Solvency
58moderate
Efficiency
54moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $BIIB

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.